BIOCON Share Price Performance
₹0
-357.75 (-100.00%)
Price ₹0
Fair Value₹429.67
Share Pricen/a
Analysis Article • Aug 08
Biocon Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
BIOCON Community Narratives
AN
Fair Value
·Fair Value ₹429.67 3.3% undervalued intrinsic discount
Biosimilars Demand Will Unlock Global Market Opportunities
0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
AN
Fair Value
·Fair Value ₹506 17.9% undervalued intrinsic discount
Growing Global Aging Demand Will Expand Affordable Biosimilars
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value ₹298.76 39.1% overvalued intrinsic discount
Rising Regulatory Scrutiny And Supply Risks Will Hamper Biosimilars
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Biosimilars Demand Will Unlock Global Market Opportunities
Biocon is leaning into the fast-growing shift toward biosimilar medicines, with new launches, bigger manufacturing capacity, and global partners that could widen its reach in diabetes and cancer care. The big question is whether it can turn that growth into steadier profits while carrying heavy debt, facing tough price competition, and navigating drug-approval delays.Read more
AN
₹429.67
3.3% undervalued intrinsic discount
Fair Value
Revenue
14.01% p.a.
Profit Margin
10.73%
Future PE
45.01x
Price in 2029
₹623.21
Growing Global Aging Demand Will Expand Affordable Biosimilars
Biocon bets that rising demand for lower-cost biologic medicines lets its biosimilars become the go-to options as more branded drugs lose protection. The upside comes from new launches, expanded manufacturing, and local supply partnerships—but intense price pressure, tough competition, and regulatory delays could derail the story.Read more
AN
₹506
17.9% undervalued intrinsic discount
Fair Value
Revenue
17.28% p.a.
Profit Margin
9.5%
Future PE
55x
Price in 2029
₹730.6
Rising Regulatory Scrutiny And Supply Risks Will Hamper Biosimilars
Biocon’s biosimilar business could face a tougher road as regulators tighten checks and countries push to make more medicines locally, which may slow new launches and raise costs. At the same time, the company’s newer medicines and partnerships could help it grow if it can move beyond older products and stay competitive.Read more
AN
₹298.76
39.1% overvalued intrinsic discount
Fair Value
Revenue
11.94% p.a.
Profit Margin
8.8%
Future PE
40.36x
Price in 2029
₹431.99
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
BIOCON: Execution On Margin Plans And Biosimilars Pipeline Will Support Measured Upside
Fair Value: ₹429.67 3.3% undervalued intrinsic discount
15 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BIOCON: Future Margin Reset Will Support Biosimilars Expansion And Leadership Transition
Fair Value: ₹506 17.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BIOCON: Tough Macro And Execution Risks Will Restrict Future P/E Upside
Fair Value: ₹298.76 39.1% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Biocon Limited Key Details
About BIOCON
- Founded
- 1978
- Employees
- 16447
- CEO
- WebsiteView website
Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Recent BIOCON News & Updates
Narrative Update • Aug 07
